SCHEDULE 13G/A: Cystic Fibrosis Foundation Discloses 9.99% Passive Stake in BiomX Inc.

The Cystic Fibrosis Foundation has filed an amendment to its Schedule 13G, disclosing a 9.99% beneficial ownership stake in BiomX Inc. as of February 27, 2025.

Summary

• The Cystic Fibrosis Foundation (CFF) filed an Amendment No. 4 to its Schedule 13G regarding its beneficial ownership in BiomX Inc.
• CFF beneficially owns 2,494,110 shares of BiomX Inc. Common Stock.
• This ownership represents 9.99% of BiomX Inc.'s Common Stock outstanding.
• The percentage is calculated based on 24,966,053 shares of Common Stock outstanding as of February 27, 2025, as provided by BiomX Inc. to CFF on March 4, 2025.
• CFF holds sole voting power and sole dispositive power over all 2,494,110 shares.
• The filing explicitly states that the securities were not acquired and are not held for the purpose of changing or influencing the control of BiomX Inc., indicating a passive investment intent.
• The reported beneficial ownership excludes shares underlying Series X Non-Voting Convertible Preferred Stock and warrants that are not presently convertible or exercisable within 60 days due to beneficial ownership limitations and/or other restrictions.

Sentiment

Score: 7

Explanation: The disclosure of a significant, passive ownership stake by a reputable foundation like the Cystic Fibrosis Foundation can be viewed positively, indicating confidence in the issuer's long-term prospects or strategic alignment with its mission. It is a routine regulatory update for a passive investor.

Positives

• A significant beneficial ownership stake (9.99%) by the Cystic Fibrosis Foundation, a reputable non-profit organization, in BiomX Inc. may signal confidence in the company's long-term prospects or strategic alignment with its mission.
• The investment is explicitly stated as passive, not intended to change or influence control, which suggests a stable and supportive shareholder.

Risks

• Beneficial ownership limitations and other restrictions prevent the immediate conversion of all Series X Non-Voting Convertible Preferred Stock and warrants held by the Cystic Fibrosis Foundation into Common Stock within 60 days.

Future Outlook

NA

Management Comments

• "The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

The investment by the Cystic Fibrosis Foundation, a leading non-profit focused on finding a cure for cystic fibrosis, suggests BiomX Inc. may be involved in developing therapies or technologies relevant to cystic fibrosis, aligning with the Foundation's mission and indicating potential strategic interest within the biotechnology sector focused on genetic diseases.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant, passive institutional investor, which may be perceived as a vote of confidence in the company.
• Company (BiomX Inc.): Confirms a substantial, non-activist shareholder base, potentially offering stability.

Key Dates

Keywords

BiomX Inc., Cystic Fibrosis Foundation, Schedule 13G, beneficial ownership, common stock, passive investment, biotechnology, pharmaceutical, SEC filing